Patient Guide: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 178 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05609968
Status: 🟢 Enrolling Now
Condition: Carcinoma, Non-Small-Cell Lung
Phase: PHASE3

Where You Can Participate

This study is available at 178 locations across the country.

Top locations include:
  • • Mobile, Alabama
  • • Clermont, Florida
  • • Miami, Florida
  • • And 175 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) - Join Clinical Trial NCTNCT05609968

How to Join This Clinical Trial - NCTNCT05609968

Learn how to participate in this PHASE3 trial studying an investigational therapy for Carcinoma, Non-Small-Cell Lung. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Carcinoma, Non-Small-Cell Lung. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Carcinoma, Non-Small-Cell Lung
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05609968 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 178 locations. Find a study site near you:

Clinical Research Site

Mobile, Alabama 36607 - United States

Status: RECRUITING

Clinical Research Site

Clermont, Florida 34711 - United States

Status: COMPLETED

Clinical Research Site

Miami, Florida 33136 - United States

Status: COMPLETED

Clinical Research Site

Orange City, Florida 32763 - United States

Status: RECRUITING

Clinical Research Site

Marietta, Georgia 30060 - United States

Status: RECRUITING

Clinical Research Site

Baton Rouge, Louisiana 70808 - United States

Status: RECRUITING

Clinical Research Site

Detroit, Michigan 48202 - United States

Status: COMPLETED

Clinical Research Site

Farmington Hills, Michigan 48334 - United States

Status: RECRUITING

Clinical Research Site

Minneapolis, Minnesota 55407 - United States

Status: RECRUITING

Clinical Research Site

Inwood, New York 11096 - United States

Status: RECRUITING

And 168 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Carcinoma, Non-Small-Cell Lung:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships